Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action
Mario A. Eisenberger*, Menachem Laufer, Nicholas J. Vogelzang, Oliver Sartor, Donald Thornton, Blake Lee Neubauer, Victoria Sinibaldi, Gary Lieskovsky, Michael A. Carducci, Mariana Zahurak, Derek Raghavan
Research output: Contribution to journal › Article › peer-review
16Scopus
citations
Fingerprint
Dive into the research topics of 'Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action'. Together they form a unique fingerprint.